N-亚硝基布美他尼SD大鼠体内致突变性风险研究

doi:10.19803/j.1672-8629.20230684

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (3): 307-312.
DOI: 10.19803/j.1672-8629.20230684

N-亚硝基布美他尼SD大鼠体内致突变性风险研究

文海若¹, 黄勤^2,Δ, 韩素芹¹, 姜华¹, 秦超¹, 石皓琨², 赵婷婷¹, 耿兴超¹, 汪祺^3,*

¹中国食品药品检定研究院国家药物安全评价监测中心,药物非临床安全评价研究北京市重点实验室,北京 100176;
²桂林南药股份有限公司,广西桂林 541004;
³中国食品药品检定研究院中药民族药检定所,北京 100050

收稿日期:2023-11-02 出版日期:2024-03-15 发布日期:2024-03-18
通讯作者: ^*汪祺,女,博士,研究员,药理毒理学。E-mail: sansan8251@sohu.com
作者简介:文海若,女,博士,研究员,遗传毒理学。^Δ为并列第一作者。
基金资助:
国家自然科学基金资助项目（82374033）

Mutagenicity risk of N-nitrosobumetanil in SD rats

WEN Hairuo¹, HUANG Qin^2,Δ, HAN Suqin¹, JIANG Hua¹, QIN Chao¹, SHI Haokun², ZHAO Tingting¹, GENG Xingchao¹, WANG Qi^3,*

¹Beijing Key Laboratory, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, Beijing 100176, China;
²Guilin Pharmaceutical Co., Ltd., Guilin Guangxi 541004, China;
³Institute of Chinese Traditional Medicine and Ethnic Medicine, National Institutes for Food and Drug Control, Beijing 100050, China

Received:2023-11-02 Online:2024-03-15 Published:2024-03-18

摘要/Abstract

摘要： 目的评价布美他尼杂质N-亚硝基布美他尼的体内致突变风险和肝细胞DNA损伤风险。方法 SD大鼠随机分为6组,分别为：溶媒对照组（溶媒为0.5%羧甲基纤维素钠）,N-亚硝胺布美他尼100、300、1 000 mg·kg^-1剂量组,阳性对照组1[N-乙基-N-亚硝基脲（ENU）,40 mg·kg^-1]、阳性对照组2[甲磺酸乙酯（EMS）, 200 mg·kg^-1]。2个阳性对照组均为每组6只动物,其余每组12只动物。大鼠连续14 d经口灌胃给予受试物N-亚硝胺布美他尼。首次给药后约14 d和约28 d后采集外周血用于Pig-a基因突变率检测,末次给药后约3 h取肝细胞开展彗星试验。结果试验期间给予N-亚硝基布美他尼未导致异常临床症状和动物体重及摄食量改变。100、300、1 000 mg·kg^-1剂量组动物肝细胞平均tail% DNA值（平均数/中位数）分别为2.90±0.38/2.34±0.46、3.58±0.27/2.87±0.51、3.45±0.59/2.21±1.44,与溶媒对照组相应数值相比未见差异,且无明显剂量效应相关性。首次给药后14 d,100、300、1 000 mg·kg^-1剂量组动物平均RBC^CD59-和RET^CD59-百万分之发生率（RBC^CD59-百万分之发生率/RET^CD59-百万分之发生率）分别为2.9±1.6/1.2±0.8、2.8±2.4/1.3±1.5、2.4±1.0/1.3±1.5;首次给药后28 d,100、300、1 000 mg·kg^-1剂量组动物RBC^CD59-百万分之发生率/RET^CD59-百万分之发生率分别为5.1±1.5/2.2±0.6、4.3±1.5/3.5±3.6、4.8±2.4/2.5±2.7。上述数值与相同时间点溶媒对照组相比均未见差异,且经统计学分析未见剂量效应相关性。结论连续经口给予N-亚硝基布美他尼14 d,SD大鼠的最大耐受量高于1 000 mg·kg^-1,未检出外周血基因突变风险和肝细胞DNA损伤风险。研究数据可为药品中遗传毒性杂质的合理监管和含N-亚硝基杂质药物的安全使用提供数据支持。

关键词: N-亚硝基布美他尼, 致突变性, 遗传毒性, SD大鼠, Pig-a基因突变试验, 彗星试验, 灌胃

Abstract: Objective To evaluate the mutagenicity risk and hepatocyte DNA damage risk of bumetanide impurity-N-nitrosobumetanil in vivo. Methods SD rats were randomly divided into six groups: control group (0.5% CMC-Na), 100 mg·kg^-1 dose group, 300 mg·kg^-1 dose group, 1 000 mg·kg^-1 dose group, positive control group 1 (N-ethyln-nitrosourea, ENU, 40 mg·kg^-1) and positive control group 2 (ethyl mesylate, EMS, 200 mg·kg^-1). Both positive control groups consisted of six animals and the other groups had twelve animals in each. Rats were administered with N-nitrosobumetanil by oral intragastric administration for fourteen days. Peripheral blood was collected at about 14 days and 28 days after the initial administration for the detection of Pig-a gene mutation rates. Liver cells were collected about 3 hours after the last administration for comet test. Results During the study, N-nitrosobumetanil did not result in abnormal clinical symptoms and there was no change in animal body mass or food intake. The averaged tail% DNA values (mean/median) of animal hepatocytes in 100 mg·kg^-1, 300 mg·kg^-1 and 1 000 mg·kg^-1 dosage groups were 2.90±0.38/2.34±0.46, 3.58±0.27/2.87±0.51 and 3.45±0.59/2.21±1.44, respectively, which showed no difference compared with the solvent control group, and no significant dose-effect correlation was observed. Fourteen days after the initial administration, the mean incidence of RBC^CD59- and RET^CD59- per million cells (RBC^CD59-/RET^CD59-) in 100 mg·kg^-1dose group, 300 mg·kg^-1dose group and 1 000 mg·kg^-1dose group were 2.9±1.6/1.2±0.8, 2.8±2.4/1.3±1.5 and 2.4±1.0/1.3±1, respectively. Twenty-eight days after the initial administration, the mean incidence of RBC^CD59- and RET^CD59- per million cell (RBC^CD59-/RET^CD59-) in the 100 mg·kg^-1dose group, 300 mg·kg^-1dose group and 1 000 mg·kg^-1dose group was 5.1±1.5/2.2±0.6, 4.3±1.5/3.5±3.6, and 4.8±2.4/2.5±2.7, respectively. The above values were not different from those of the solvent control group at the same time point, and no correlation of dose effect was observed by statistical analysis. Conclusion After fourteen days of oral administration of N-nitrosobumetanilis, the maximum tolerance of SD rats exceeds 1 000 mg·kg^-1, and the risk of peripheral blood gene mutation and hepatocyte DNA damage is not detected. The data can be used to back up the regulation of genotoxic impurities in drugs and the safe use of drugs containing N-nitroso impurities.

Key words: N-nitrosobumetanil, mutagenicity, genotoxicity, SD rat, Pig-a gene mutation assay, comet assay, intragastric administration

中图分类号:

R965

文海若, 黄勤, 韩素芹, 姜华, 秦超, 石皓琨, 赵婷婷, 耿兴超, 汪祺. N-亚硝基布美他尼SD大鼠体内致突变性风险研究[J]. 中国药物警戒, 2024, 21(3): 307-312.

WEN Hairuo, HUANG Qin, HAN Suqin, JIANG Hua, QIN Chao, SHI Haokun, ZHAO Tingting, GENG Xingchao, WANG Qi. Mutagenicity risk of N-nitrosobumetanil in SD rats[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 307-312.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230684

https://www.zgywjj.com/CN/Y2024/V21/I3/307

参考文献

[1] PARK JE, SEO JE, LEE JY, et al.Distribution of seven N-nitrosamines in food[J]. Toxicol Res, 2015, 31: 279-288.
[2] GE YQ, YE XX, LE J, et al.Research progress on toxicity and detection methods of N-nitrosamines genotoxic impurities[J].Journal of Pharmaceutical Analysis(药物分析杂志), 2020, 40(1): 83-89.
[3] SCHLINGEMANN J, BURNS MJ, PONTING DJ, et al.The landscape of potential small and drug substance related nitrosamines in pharmaceuticals[J]. J Pharm Sci, 2023, 112(5):1287-1304.
[4] LYU G, LIN XH.Research progress on health hazards and detection technology of NDMA in drugs[J].Occup and Health(职业与健康), 2021, 37(12): 1720-1723, 1728.
[5] WU Y, XU Q, QIAN Y, et al.Determination and risk analysis for potential N-nitrosamines in azithromycin injection[J].Chinese Journal of New Drugs(中国新药杂志), 2021, 30(21): 1998-2002.
[6] ADAMSON RH, CHABNER BA.The finding of N-Nitrosodimethylamine in common medicines[J]. The Oncologist, 2020, 25(6): 460-462.
[7] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R2)[EB/OL]. (2023-07-18)[2023-11-24].https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m7r2-guideline-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf.
[8] YE Q, GENG XC, ZHANG HZ, et al.Regulatory strategies and reflections on genotoxic impurities of nitrosamines[J].Chinese Pharmaceutical Affairs(中国药事), 2021, 35(2): 127-137.
[9] SHI FJ, WANG QJ.Toxicological evaluation strategy of genotoxicimpurities[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(3): 232-235.
[10] LÖSCHER W, KAILA K. CNS pharmacology of NKCC1 inhibitors[J]. Neuropharmacology, 2022, 205: 108910.
[11] OECD. Test no. 489: In Vivo Mammalian Alkaline Comet Assay[EB/OL].(2016-07-29)[2023-10-22]. https://www.oecd.org/env/test-no-489-in-vivo-mammalian-alkaline-comet-assay-9789264264885-en.htm.
[12] OECD. Test no. 470: mammalian erythrocyte pig-a gene mutation assay[EB/OL].(2022-06-30)[2023-10-22]. https://www.oecd-ilibrary.org/environment/test-no-470-mammalian-erythrocyte-pig-a-gene-mutation-assay_4faea90e-en;jsessionid=dBHn54MRqxNRbv7GH8kJ-ou3I5M20JdGQH4OVl7K.ip-10-240-5-189.
[13] National Food and Drug Administration. Order No. 34 of the National Food and Drug Administration: Quality Management Standards for Non Clinical Drug Research[EB/OL].(2017-07-21)[2023-10-22].https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_2959b53d3b6a429e866c514a76a790db.html.
[14] CHEN G, WEN H, MAO Z, et al.Assessment of the Pig-a, micronucleus, and comet assay endpoints in rats treated by acute or repeated dosing protocols with procarbazine hydrochloride and ethyl carbamate[J]. Environ Mol Mutagen, 2019, 60(1): 56-71.
[15] KONG X.Research progress of detection methods for N-nitrosamines genotoxic impurities in drugs[J]. Tianjin Pharmacy(天津药学), 2022, 34(1): 62-67.
[16] SHAKLEYA D, ASMELASH B, ALAYOUBI A, et al.Bumetanide as a model NDSRI substrate: N-nitrosobumetanideimpurity formation and its inhibition in bumetanidetablets[J].J Pharm Sci J, 2023, 112(12): 3075-3087.
[17] THRESHER A, FOSTER R, PONTING DJ, et al.Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data[J]. Regul Toxicol Pharmacol, 2020, 116: 104749.
[18] WEN HR, YE Q, YANG Y, et al.Gene mutation risk assessment of phenolic compounds[J]. Chinese Journal of pharmacovigilance(中国药物警戒), 2022, 19(8):868-872.
[19] FDA. Nitrosamines as Impurities in Drugs-Health Risk Assessment and Mitigation Public Workshop [EB/OL].(2021-05-29)[2023-10-22].https://www.fda.gov/drugs/news-events-human-drugs/nitrosamines-impurities-drugs-health-risk-assessment-and-mitigation-public-workshop-03292021.
[20] CHEN GF, WANG YN, WANG D, et al.Research advances for Pig -a gene mutation assay[J] Carcinogenesis, Teratogenesis& Mutagenesis(癌变·畸变·突变), 2019, 31(6): 492-497.
[21] EMA. SPECIFIC CONTRACT SC03:Endogenous formation of nitrosamines from drug substances (GITox)[EB/OL].(2022-06-30)[2023-10-22].https://www.encepp.eu/encepp/openAttachment/fullProtocol/49088.
[22] EMA. Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products[EB/OL].(2023-10-02)[2023-10-22].https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders/applicants-chmp-opinion-article-53-regulation-ec-no-726/2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf.

N-亚硝基布美他尼SD大鼠体内致突变性风险研究

Mutagenicity risk of N-nitrosobumetanil in SD rats

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	杨明翰, 乔美玲, 骆骄阳, 杨美华, 盛萍. 多伞阿魏抗胃癌活性部位的急性毒性试验研究[J]. 中国药物警戒, 2023, 20(8): 880-884.
[2]	沈宁宁, 刘昱甫, 茹毅, 师卓, 杨春启, 倪喆鑫, 肖成荣, 马增春, 王宇光, 高月. 麦冬皂苷D对小鼠力竭游泳抗疲劳作用的研究[J]. 中国药物警戒, 2023, 20(7): 749-753.
[3]	王荣, 刘自群, 王娜娜, 谭雄, 张怡心, 杨宽, 秦蓓. 脯氨酸丹参素冰片酯对小鼠急性毒性研究[J]. 中国药物警戒, 2023, 20(7): 754-757.
[4]	聂雨楠, 张丽, 邵明香, 高莉, 闫明. 类叶升麻苷大鼠安全性评价[J]. 中国药物警戒, 2023, 20(7): 758-762.
[5]	林铌, 叶倩, 耿兴超, 王雪, 靳洪涛, 文海若. 杂质5-羟甲基糠醛及其二聚体和代谢产物遗传毒性研究[J]. 中国药物警戒, 2023, 20(2): 157-162.
[6]	崔苗, 王涛, 宋延平, 杨彦平, 周欣. 注射用炎琥宁的遗传毒性研究[J]. 中国药物警戒, 2022, 19(9): 973-976.
[7]	文海若, 叶倩, 杨颖, 宋捷, 汪祺, 王雪. 苯酚类化合物基因突变风险评价研究[J]. 中国药物警戒, 2022, 19(8): 868-872.
[8]	黄露, 刘博, 王岩, 范慧红, 张庆生. 核苷类抗病毒药物质量控制研究进展[J]. 中国药物警戒, 2022, 19(6): 692-696.
[9]	文海若, 王亚楠, 姜华, 王雪, 汪祺, 马双成. 大黄素体内遗传毒性风险评价[J]. 中国药物警戒, 2022, 19(6): 635-640.
[10]	汪祺, 文海若, 杨建波, 王莹, 李妍怡, 马双成, 张玉杰. 何首乌水提物给药后大鼠体内成分研究[J]. 中国药物警戒, 2022, 19(6): 620-625.
[11]	徐百卉, 王恩力, 郑成成, 徐娇艳, 李贝贝, 张晓红, 周宗仪, 王永刚, 姚景春. 荆防颗粒浸膏大鼠90天重复灌胃给药毒性研究[J]. 中国药物警戒, 2022, 19(5): 510-514.
[12]	郑成成, 徐百卉, 徐娇艳, 王会萍, 李贝贝, 张晓红, 孙颖, 姚景春, 王恩力. 荆防颗粒浸膏大鼠灌胃给药围产期发育毒性研究[J]. 中国药物警戒, 2022, 19(5): 498-504.
[13]	郑成成, 王会萍, 徐百卉, 徐娇艳, 李贝贝, 张晓红, 张伟, 孙颖, 王恩力. 荆防颗粒浸膏对大鼠胚胎-胎仔发育毒性研究[J]. 中国药物警戒, 2022, 19(5): 493-497.
[14]	王姝廷, 李慧, 王江雪, 张紫璇, 牟文波, 郭新苗, 叶向锋, 靳洪涛. Beagle犬灌胃厄多司坦盐酸氨溴索混合物的急性和亚慢性毒性研究[J]. 中国药物警戒, 2021, 18(1): 24-29.
[15]	高梅, 马会, 陈凯, 张岱州. 注射用右旋雷贝拉唑钠的遗传毒性评价[J]. 中国药物警戒, 2020, 17(9): 559-563.